Q2 2025 |
58 |
$237M |
+$18.7M |
-$17.8M |
+$877K |
THRY, PDFS, GENI, INSE, CTLP
|
13F-HR |
8/13/2025, 12:26 PM |
Q1 2025 |
57 |
$236M |
+$22.3M |
-$19.4M |
+$2.9M |
THRY, GENI, INSE, PDFS, PRMB
|
13F-HR |
5/14/2025, 02:45 PM |
Q4 2024 |
54 |
$265M |
+$57.1M |
-$67.5M |
-$10.5M |
THRY, PDFS, GENI, INSE, AIP
|
13F-HR |
2/12/2025, 05:39 PM |
Q3 2024 |
53 |
$290M |
+$26.1M |
-$26.2M |
-$188K |
THRY, PDFS, ITI, GENI, ASPN
|
13F-HR |
11/12/2024, 09:20 AM |
Q2 2024 |
53 |
$242M |
+$18.6M |
-$26.6M |
-$7.96M |
THRY, PDFS, ASPN, INSE, GENI
|
Restatement |
8/13/2024, 03:57 PM |
Q1 2024 |
55 |
$284M |
+$28.4M |
-$27.9M |
+$528K |
THRY, ITI, PDFS, ASPN, INSE
|
13F-HR |
5/14/2024, 09:50 AM |
Q4 2023 |
50 |
$282M |
|
|
|
THRY, ASPN, PDFS, ITI, GENI
|
13F-HR |
2/9/2024, 02:19 PM |
Q3 2023 |
|
|
|
|
|
|
13F-NT |
11/14/2023, 12:53 PM |